1
|
Budisteanu M, Papuc S, Erbescu A, Iliescu C, Dobre M, Barca D, Tarta‑arsene O, Motoescu C, Dica A, Sandu C, Anghelescu C, Craiu D, Arghir A. Clinical and genomic findings in brain heterotopia: Report of a pediatric patient cohort from Romania. Exp Ther Med 2021; 23:101. [PMID: 34976143 PMCID: PMC8674960 DOI: 10.3892/etm.2021.11024] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Accepted: 06/09/2021] [Indexed: 11/08/2022] Open
Abstract
Brain heterotopia is a group of rare malformations with a heterogeneous phenotype, ranging from asymptomatic to a severe clinical picture (drug-resistant epilepsy, severe developmental delay). The etiology is multifactorial, including both genetic and environmental factors. In the present study, a cohort of 15 pediatric patients with brain heterotopia were investigated by clinical examination, electroencephalographic studies, brain imaging, and genomic tests. Most of the patients had epileptic seizures, often difficult to control with one antiepileptic drug; another frequent characteristic in the cohort was developmental delay or intellectual disability, in some cases associated with behavioral problems. The genomic studies revealed an interstitial 22q11.2 microduplication, an anomaly not reported previously in heterotopia patients. Comparing the cohort of the present study with that of a previous series of heterotopia patients, both adult and pediatric, similar aspects, such as the high frequency of drug-resistant epilepsy were observed as well as some differences, such as no systemic malformations and no cases with fatal evolution. The current findings add new data to existing knowledge on a rare heterogeneous disorder. The detailed clinical description, including the epilepsy phenotypes, and genomic profiles bring new insights into a group of disorders, yet to be fully understood.
Collapse
Affiliation(s)
- Magdalena Budisteanu
- Medical Genetics Laboratory, Victor Babes National Institute of Pathology, 050096 Bucharest, Romania
| | - Sorina Papuc
- Medical Genetics Laboratory, Victor Babes National Institute of Pathology, 050096 Bucharest, Romania
| | - Alina Erbescu
- Medical Genetics Laboratory, Victor Babes National Institute of Pathology, 050096 Bucharest, Romania
| | - Catrinel Iliescu
- Department of Pediatric Neurology, Expertise Centre for Rare Diseases in Pediatric Neurology, Member of The EpiCARE European Reference Network, ‘Prof. Dr. Alex. Obregia’ Clinical Hospital, 041914 Bucharest, Romania
| | - Maria Dobre
- Medical Genetics Laboratory, Victor Babes National Institute of Pathology, 050096 Bucharest, Romania
| | - Diana Barca
- Department of Pediatric Neurology, Expertise Centre for Rare Diseases in Pediatric Neurology, Member of The EpiCARE European Reference Network, ‘Prof. Dr. Alex. Obregia’ Clinical Hospital, 041914 Bucharest, Romania
| | - Oana Tarta‑arsene
- Department of Pediatric Neurology, Expertise Centre for Rare Diseases in Pediatric Neurology, Member of The EpiCARE European Reference Network, ‘Prof. Dr. Alex. Obregia’ Clinical Hospital, 041914 Bucharest, Romania
| | - Cristina Motoescu
- Department of Pediatric Neurology, Expertise Centre for Rare Diseases in Pediatric Neurology, Member of The EpiCARE European Reference Network, ‘Prof. Dr. Alex. Obregia’ Clinical Hospital, 041914 Bucharest, Romania
| | - Alice Dica
- Department of Pediatric Neurology, Expertise Centre for Rare Diseases in Pediatric Neurology, Member of The EpiCARE European Reference Network, ‘Prof. Dr. Alex. Obregia’ Clinical Hospital, 041914 Bucharest, Romania
| | - Carmen Sandu
- Department of Pediatric Neurology, Expertise Centre for Rare Diseases in Pediatric Neurology, Member of The EpiCARE European Reference Network, ‘Prof. Dr. Alex. Obregia’ Clinical Hospital, 041914 Bucharest, Romania
| | - Cristina Anghelescu
- Department of Pediatric Neurology, Expertise Centre for Rare Diseases in Pediatric Neurology, Member of The EpiCARE European Reference Network, ‘Prof. Dr. Alex. Obregia’ Clinical Hospital, 041914 Bucharest, Romania
| | - Dana Craiu
- Department of Pediatric Neurology, Expertise Centre for Rare Diseases in Pediatric Neurology, Member of The EpiCARE European Reference Network, ‘Prof. Dr. Alex. Obregia’ Clinical Hospital, 041914 Bucharest, Romania
| | - Aurora Arghir
- Medical Genetics Laboratory, Victor Babes National Institute of Pathology, 050096 Bucharest, Romania
| |
Collapse
|
5
|
Berrou E, Adam F, Lebret M, Fergelot P, Kauskot A, Coupry I, Jandrot-Perrus M, Nurden A, Favier R, Rosa JP, Goizet C, Nurden P, Bryckaert M. Heterogeneity of Platelet Functional Alterations in Patients With Filamin A Mutations. Arterioscler Thromb Vasc Biol 2013; 33:e11-8. [DOI: 10.1161/atvbaha.112.300603] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
We examined platelet functions in 4 unrelated patients with filaminopathy A caused by dominant mutations of the X-linked filamin A (
FLNA
) gene.
Methods and Results—
Patients P1, P2, and P4 exhibited periventricular nodular heterotopia, heterozygozity for truncating
FLNA
mutations, and thrombocytopenia (except P2). P3 exhibited isolated thrombocytopenia and heterozygozity for a p.Glu1803Lys
FLNA
mutation. Truncated FLNa was undetectable by Western blotting of P1, P2, and P4 platelets, but full-length FLNa was detected at 37%, 82%, and 57% of control, respectively. P3 FLNa (p.Glu1803Lys and full-length) was assessed at 79%. All patients exhibited a platelet subpopulation negative for FLNa. Platelet aggregation, secretion, glycoprotein VI signaling, and thrombus growth on collagen were decreased for P1, P3, and P4, but normal for P2. For the 2 patients analyzed (P1 and P4), spreading was enhanced and, more markedly, in FLNa-negative platelets, suggesting that FLNa negatively regulates cytoskeleton reorganization. Platelet adhesion to von Willebrand factor under flow correlated with platelet full-length FLNa content: markedly reduced for P1 and P4 and unchanged for P2. Interestingly, von Willebrand factor flow adhesion was increased for P3, consistent with a gain-of-function effect enhancing glycoprotein Ib-IX-V/von Willebrand factor interaction. These results are consistent with a positive role for FLNa in platelet adhesion under high shear.
Conclusion—
FLNA
mutation heterogeneity correlates with different platelet functional impacts and points to opposite regulatory roles of FLNa in spreading and flow adhesion under shear.
Collapse
Affiliation(s)
- Eliane Berrou
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Frédéric Adam
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Marilyne Lebret
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Patricia Fergelot
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Alexandre Kauskot
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Isabelle Coupry
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Martine Jandrot-Perrus
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Alan Nurden
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Rémi Favier
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Jean-Philippe Rosa
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Cyril Goizet
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Paquita Nurden
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| | - Marijke Bryckaert
- From the INSERM, U770, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Paris-Sud, Le Kremlin Bicêtre, France (E.B., F.A., M.L., A.K., J-P.R., M.B.); Université Bordeaux Segalen, Laboratoire Maladies Rares: Génétique et Métabolisme (MRGM), EA 4576, Bordeaux, France (P.F., I.C., C.G.); CHU Bordeaux, Centre de Référence Anomalies du Développement Embryonnaire, Service de Génétique Médicale, Hôpital Pellegrin, Bordeaux, France (P.F., C.G.); INSERM, U698, Paris, France (M.J
| |
Collapse
|